-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 27, Syndax Pharmaceuticals (hereinafter referred to as "Syndax") and Incyte jointly announced that the two parties have reached a global cooperation and exclusive license agreement to jointly develop and commercialize Syndax's anti-CSF-1R monoclonal The antibody axatilimab is used to treat chronic graft-versus-host disease (cGVHD) and other fibrotic diseases
.
Under the terms of the agreement, Syndax will receive an upfront payment of US$117 million, an equity investment of US$35 million, and potential regulatory, development and commercial milestone payments of up to US$450 million
The terms of cooperation show that Inset will lead the global commercial activities of axatilimab for all indications
.
Syndax will receive double-digit royalties from sales outside the United States and will retain the option to jointly promote axatilimab in the United States
Chronic graft versus host disease (cGVHD) is a serious and potentially fatal complication after allogeneic hematopoietic stem cell transplantation (HSCT)
.
Nearly 40% of HSCT transplant patients may develop cGVHD, affecting approximately 14,000 patients in the United States
Idiopathic pulmonary fibrosis (IPF) is a serious, life-limiting chronic lung disease characterized by pulmonary fibrosis and scarring.
The median survival period after diagnosis is 3-5 years
.
Patients with IPF experience debilitating symptoms, including progressive shortness of breath, especially fatigue, chronic cough, fatigue, weakness, and chest discomfort
Axatilimab is a monoclonal antibody under development.
It was originally developed by UCB (UCB).
In 2016, Syndax and UCB signed an exclusive worldwide license to obtain the right to develop the drug
.
Axatilimab has obtained orphan drug designation granted by the US FDA for the treatment of cGVHD and IPF
Note: The original text has been deleted
Reference materials:
[1] Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases.
